The U.S. Food and Drug Administration (FDA) has approved a new simplified monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) from Johnson & Johnson. The treatment, administered in combination with oral LAZCLUZE® (lazertinib), is indicated for first-line treatment of EGFR-mutated advanced non-small cell lung cancer. The monthly dosing maintains consistent safety and efficacy with previously approved bi-weekly dosing and aims to reduce the frequency of treatment visits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602170800PR_NEWS_USPR_____CG88492) on February 17, 2026, and is solely responsible for the information contained therein.